Organogenesis (ORGO) Competitors $4.88 +0.41 (+9.11%) Closing price 03:59 PM EasternExtended Trading$4.88 +0.01 (+0.16%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. TARS, OCUL, AGIO, DNLI, GLPG, IDYA, SRPT, BLTE, HRMY, and IRONShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Tarsus Pharmaceuticals (TARS), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), Belite Bio (BLTE), Harmony Biosciences (HRMY), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Tarsus Pharmaceuticals Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics Galapagos IDEAYA Biosciences Sarepta Therapeutics Belite Bio Harmony Biosciences Disc Medicine Tarsus Pharmaceuticals (NASDAQ:TARS) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability. Do institutionals & insiders have more ownership in TARS or ORGO? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings & valuation, TARS or ORGO? Organogenesis has higher revenue and earnings than Tarsus Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M13.18-$115.55M-$2.33-24.52Organogenesis$429.31M1.44$860K-$0.14-34.84 Do analysts prefer TARS or ORGO? Tarsus Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 16.71%. Organogenesis has a consensus price target of $7.50, suggesting a potential upside of 53.78%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is TARS or ORGO more profitable? Organogenesis has a net margin of -1.92% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Organogenesis' return on equity of -0.37% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Organogenesis -1.92%-0.37%-0.20% Does the media favor TARS or ORGO? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.76 beat Tarsus Pharmaceuticals' score of 1.53 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, TARS or ORGO? Tarsus Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. SummaryOrganogenesis beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$618.69M$2.81B$5.83B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-34.8322.6631.1625.99Price / Sales1.44760.87474.86122.97Price / Cash21.95173.2237.1558.38Price / Book2.655.879.116.38Net Income$860K$31.83M$3.26B$265.56M7 Day Performance3.11%1.78%2.06%1.89%1 Month Performance1.18%4.33%5.08%1.23%1 Year Performance77.35%11.50%31.26%21.10% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.2896 of 5 stars$4.88+9.1%$7.50+53.8%+58.0%$618.69M$429.31M-34.83950Positive NewsTARSTarsus Pharmaceuticals1.9359 of 5 stars$54.61+0.7%$66.67+22.1%+116.9%$2.29B$182.95M-23.4450News CoveragePositive NewsOCULOcular Therapeutix3.9475 of 5 stars$12.31-2.5%$17.20+39.7%+31.4%$2.20B$63.72M-9.62230AGIOAgios Pharmaceuticals4.3317 of 5 stars$37.45+1.2%$56.33+50.4%-18.9%$2.15B$36.50M3.40390DNLIDenali Therapeutics4.204 of 5 stars$14.82+0.8%$33.62+126.8%-39.1%$2.15B$330.53M-5.29430News CoverageGLPGGalapagos0.1338 of 5 stars$32.91+1.4%$25.33-23.0%+26.6%$2.14B$275.61M0.001,310IDYAIDEAYA Biosciences4.519 of 5 stars$24.75+1.7%$48.09+94.3%-38.0%$2.13B$7M-6.5380Positive NewsSRPTSarepta Therapeutics4.6432 of 5 stars$20.99-3.8%$43.63+107.8%-86.0%$2.13B$1.90B-24.131,372Trending NewsAnalyst ForecastShort Interest ↑BLTEBelite Bio2.5894 of 5 stars$64.95-2.5%$96.67+48.8%+32.5%$2.12BN/A-41.9010HRMYHarmony Biosciences4.5893 of 5 stars$36.41-1.2%$51.00+40.1%+1.3%$2.12B$714.73M11.75200Positive NewsIRONDisc Medicine3.4812 of 5 stars$58.84-1.7%$96.18+63.5%+21.2%$2.08BN/A-13.1630 Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives Galapagos Alternatives IDEAYA Biosciences Alternatives Sarepta Therapeutics Alternatives Belite Bio Alternatives Harmony Biosciences Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access